2025-23707Notice

FDA's Guide to Settling Drug Debates Without Drama

Published Date: 12/23/2025

Notice

Summary

The FDA just released final guidance to help drug companies and FDA staff settle scientific disagreements through formal dispute resolution and hearings. This update affects anyone involved in drug reviews under Section 505G and aims to make the process clearer and fairer. The guidance is effective now, helping save time and avoid costly delays in drug approvals.

Analyzed Economic Effects

5 provisions identified: 3 benefits, 2 costs, 0 mixed.

Final 505G Dispute-Resolution Guidance Published

On December 23, 2025 the FDA announced final guidance titled "Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act." The guidance gives recommendations for industry and review staff about formal dispute resolution (FDR) and administrative hearings for scientific or medical disputes between CDER and eligible requestors or sponsors of drugs subject to a Final Order under section 505G.

Paperwork Reduction Act Exemption for 505G Filings

Under section 505G(o) the Paperwork Reduction Act (PRA) does not apply to collections of information made under section 505G, so clearance by OMB under the PRA is not required for these collections. The guidance also references existing OMB-approved collections (for example, OMB control numbers 0910-0340 and 0910-0001).

Scope Limits and Submission Conduct Clarified

The final guidance clarifies that its recommendations are limited to FDR under section 505G(b)(2)(A)(iv)(III) and 505G(b)(4)(D)(iii) and to hearings under section 505G(b)(3). FDA removed language that could imply submitting new information outside of, or during, FDR and discouraged eligible requestors or sponsors from actively engaging other FDA entities or pursuing other regulatory or legal pathways on the same matter at the same time.

Electronic-Only Submissions Required

The guidance implements section 505G(j), which requires that all submissions related to section 505G must be in electronic format. Entities participating in FDR or hearings under section 505G must prepare and submit required materials electronically.

Consolidated Hearings Allowed for Same Order

The guidance describes procedures for consolidated proceedings and notes that under section 505G(b)(3)(C)(ii) a single hearing may be conducted if more than one request is submitted with respect to the same administrative order. The guidance also outlines best practices for consolidated appeals as required by section 505G(l)(4).

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
12/23/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML
Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in